Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Drugs used in chemotherapy, such as bleomycin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of bleomycin is more effective when given together with etoposide and cisplatin in treating metastatic germ cell cancer of the testicles.

PURPOSE: This randomized phase III trial is studying two different schedules of bleomycin to compare how well they work when given together with etoposide and cisplatin in treating patients with metastatic germ cell cancer of the testicles.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen Mary University of London
• Treatments: Bleomycin; Cisplatin; Etoposide; Etoposide phosphate

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of metastatic germ cell cancer of the testes

• Good-prognosis disease

• Eligible for treatment with bleomycin, etoposide, and cisplatin

PATIENT CHARACTERISTICS:

• Creatinine clearance ≥ 60 mL/min

• No other prior or concurrent malignancy except basal cell skin cancer

• No other major systemic illness

• No impaired respiratory function, including any of the following:

• Shortness of breath on minimal exertion

• Hypoxia at rest

• Carbon monoxide transfer, total lung capacity, and FEV_1 > 60% of predicted

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy